Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Zetomipzomib - Kezar Life Sciences

Next Previous
Drug Profile

Zetomipzomib - Kezar Life Sciences

Alternative Names: KZR-616

Latest Information Update: 22 May 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Onyx Pharmaceuticals
  • Developer Everest Medicines; Kezar Life Sciences
  • Class Anti-inflammatories; Antianaemics; Antirheumatics; Cyclopentanes; Hepatoprotectants; Morpholines; Small molecules; Urologics
  • Mechanism of Action Proteasome inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Dermatomyositis; Polymyositis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Autoimmune hepatitis; Dermatomyositis; Polymyositis; Systemic lupus erythematosus
  • Preclinical Haemophagocytic lymphohistiocytosis
  • Suspended Lupus nephritis
  • No development reported Autoimmune disorders

Most Recent Events

  • 31 Mar 2026 Kezar Life Sciences completes a Type C meeting with the US FDA related to the regulatory pathway for development of zetomipzomib in autoimmune hepatitis, in March 2026
  • 09 Jan 2026 Kezar Life Sciences receives FDA agreement for a Type C meeting to discuss the development of Zetomipzomib in Autoimmune hepatitis (AIH)
  • 09 Jan 2026 Kezar Life Sciences plans a Type C meeting with the Division of Hepatology and Nutrition for Zetomipzomib in Autoimmune hepatitis (AIH) to discuss the clinical development pathway in the first quarter of 2026

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top